Drug · CHEMBL4298024
BINTRAFUSP ALFA
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BINTRAFUSP ALFA. Drugs and targets, record CHEMBL4298024. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL4298024
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets4
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Programmed cell death 1 ligand 1 binding agent | BINDING AGENT | https://conductscience.org/library/genes/29126 |
| TGFB1 | Transforming growth factor beta | Transforming growth factor beta binding agent | BINDING AGENT | https://conductscience.org/library/genes/7040 |
| TGFB2 | Transforming growth factor beta | Transforming growth factor beta binding agent | BINDING AGENT | https://conductscience.org/library/genes/7042 |
| TGFB3 | Transforming growth factor beta | Transforming growth factor beta binding agent | BINDING AGENT | https://conductscience.org/library/genes/7043 |
Source ChEMBL
Diseases40
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 40Source Open Targets
See all 40 diseasesTrials55
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02723955 | Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) | Phase 1 | 829 | 2024-12-27 | bintrafusp alfa | Its name | ClinicalTrials.gov |
| NCT02517398 | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors | Phase 1 | 600 | 2024-05-03 | msb0011359c | Its name | ClinicalTrials.gov |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | Phase 2/3 | 309 | 2022-06-13 | bintrafusp alfa | Its name | ClinicalTrials.gov |
| NCT03631706 | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 3 | 304 | 2022-06-29 | bintrafusp alfa | Its name | ClinicalTrials.gov |
| NCT03833661 | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | Phase 2 | 159 | 2022-01-10 | m7824 | Its name | ClinicalTrials.gov |
| NCT03840902 | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | 153 | 2024-01-16 | m7824 | Its name | ClinicalTrials.gov |
| NCT04246489 | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | Phase 2 | 146 | 2023-05-09 | bintrafusp alfa | Its name | ClinicalTrials.gov |
| NCT02699515 | MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors | Phase 1 | 114 | 2024-11-18 | bintrafusp alfa | Its name | ClinicalTrials.gov |
| NCT03840915 | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | Phase 1/2 | 70 | 2023-08-21 | bintrafusp alfa | Its name | ClinicalTrials.gov |
| NCT03493945 | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) | Phase 1/2 | 59 | 2025-06-08 | bintrafusp alfa | Its name | ClinicalTrials.gov |
1 to 10 of 55
See all 55 trialsComparisons in its trials31
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| M7824 vs Pembrolizumab: deaths from any cause | 49 of 151 | 43 of 152 | 303 | NCT03631706 | Trial comparisons |
| M7824 vs Pembrolizumab: serious adverse events | 90 of 151 | 61 of 152 | 303 | NCT03631706 | Trial comparisons |
| cCRT Plus M7824 Followed by M7824 vs cCRT Plus Placebo Followed by Durvalumab: deaths from any cause | 13 of 75 | 5 of 78 | 153 | NCT03840902 | Trial comparisons |
| cCRT Plus M7824 Followed by M7824 vs cCRT Plus Placebo Followed by Durvalumab: serious adverse events | 43 of 74 | 31 of 77 | 151 | NCT03840902 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 30 of 30 | 26 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious Grade ≥3 Adverse Events Considered Related to Study Treatment of M7824 | 6 of 30 | 4 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: deaths from any cause | 18 of 30 | 22 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: serious adverse events | 19 of 30 | 21 of 26 | 56 | NCT03427411 | Trial comparisons |
Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 47 of 47 | 3 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: deaths from any cause | 28 of 47 | 0 of 3 | 50 | NCT04287868 | Trial comparisons |
1 to 10 of 31
See all 31 comparisons in its trialsPapers from its trials36
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL4298024
GET https://conductscience.org/api/drugs/v1/CHEMBL4298024/diseases?page=2